The role of vancomycin in the treatment paradigm

Area of Science:

• Infectious Diseases
• Pharmacology
• Microbiology

Background:

• Vancomycin introduced in 1956 for penicillin-resistant Staphylococcus aureus.
• Limited initial use due to toxicity and competing antibiotics.
• Became treatment of choice for methicillin-resistant Staphylococcus aureus (MRSA).

Purpose of the Study:

• To review the historical use and evolving efficacy of vancomycin.
• To address recent concerns regarding vancomycin's effectiveness against staphylococcal infections.

Main Methods:

• Historical review of vancomycin's introduction and clinical application.
• Analysis of comparative bactericidal activity and clinical outcomes.
• Examination of factors influencing current vancomycin efficacy.

Main Results:

• Vancomycin demonstrated rapid bactericidal activity against susceptible S. aureus strains.
• Nafcillin remained preferred for staphylococcal bacteremia due to lower failure rates.
• Emergence of MRSA established vancomycin as the primary treatment.
• Increasing minimum inhibitory concentrations and altered killing kinetics raise efficacy concerns.

Conclusions:

• Vancomycin's role shifted from a limited-use drug to a critical agent for MRSA.
• Current trends suggest a potential decline in vancomycin's efficacy against staphylococci.
• Further research is needed to understand and address vancomycin resistance and suboptimal outcomes.